Ефективність хірургічного лікування неоваскулярної глаукоми із застосуванням anti-VEGF препаратів

U.P. Sydorchuk; I.Ia. Novytskyy

doi:10.31288/oftalmolzh2023138

Authors

U.P. Sydorchuk Danylo Halytsky Lviv National Medical University
I.Ia. Novytskyy Danylo Halytsky Lviv National Medical University

DOI:

https://doi.org/10.31288/oftalmolzh2023138

Keywords:

secondary neovascular glaucoma, trabeculectomy with the formation of a filtering channel, Ex-PRESS mini-shunt surgery, intravitreal anti-VEGF injection, intraocular pressure

Abstract

Background: Secondary neovascular glaucoma (NVG) is a refractory type of glaucoma, with its surgical treatment being a challenge.

Purpose: To compare the efficacy of trabeculectomy (TE) with the formation of a filtering channel versus Ex-PRESS mini shunt surgery in surgical plus anti-VEGF treatment for NVG.

Material and Methods: This study included 32 neovascular glaucoma patients (32 eyes) that received surgery due to elevated intraocular pressure (IOP > 26 mmHg) not controlled by glaucoma medication. Mean patient age was 65.2 ± 10.1 years. NVG was caused by diabetic mellitus in 22 eyes and central retinal or branch vein occlusion in 10 eyes. The TE group (23 patients) underwent our modified TE procedure (with the formation of a filtering channel), and the Ex-PRESS group (9 patients), an Ex-PRESS mini-shunt surgery. A 0.5-mg intravitreal ranibizumab injection was administered 3-5 days before surgery.

Results: Study eyes had regression or resolution of iris neovascularization 3-5 days after intravitreal ranibizumab injection. In the total sample of patients, mean IOP changed from 30.9 ± 7.1 mm Hg before surgery to 17.0 ± 3.6 mm Hg at day 7 and 22.1 ± 2.9 mm Hg at 12 months. In the TE group, mean IOP changed from 31.3 ± 8.4 mm Hg before surgery to 16.7 ± 3.7 mm Hg at day 7 and 21.6 ± 2.5 mm Hg at 12 months. In the Ex-PRESS group, mean IOP changed from 30.0 ± 1.7 mm Hg before surgery to 18.0 ± 3.2 mm Hg at day 7 and 23.3 ± 2.3 mm Hg at 12 months. Mean number of anti-glaucoma medications used reduced from 2.4 ± 0.7 before surgery to 1.3 ± 0.6 at 1 month in the total sample of patients, from 2.4 ± 0.8 before surgery to 1.0 ± 0.6 at 1 month in the TE group, and from 2.6 ± 0.5 before surgery to 1.5 ± 0.7 at 1 month in the Ex-PRESS group.

Conclusion: Our modification of TE (with the formation of a filtering channel) combined with preoperative 0.5-mg intravitreal ranibizumab injection is an effective treatment for NVG, and is not less effective than Ex-PRESS mini-shunt surgery with preoperative 0.5-mg intravitreal ranibizumab injection for this purpose.

Author Biographies

U.P. Sydorchuk, Danylo Halytsky Lviv National Medical University

Department of Ophthalmology, School of Post-Graduate Education, Danylo Halytsky Lviv National Medical University

I.Ia. Novytskyy, Danylo Halytsky Lviv National Medical University

Department of Ophthalmology, School of Post-Graduate Education, Danylo Halytsky Lviv National Medical University

References

Палько В. Ефективність комбінованого лікування хворих на вторинну неоваскулярну глаукому. Здоров'я України 21 сторіччя. 2018;8(429):70.

AlSemari MA, Al Owaifeer AM, AlMubarak F, Turjoman A, Osman EA. ExPress mini shunt device with trabeculectomy surgery in patients with uncontrolled glaucoma of Middle Eastern descent. Saudi J Ophthalmol. 2021 Feb 27;34(3):177-181. https://doi.org/10.4103/1319-4534.310416

Arimura S, Iwasaki K, Orii Y, Takamura Y, Inatani M. Comparison of 5-year outcomes between trabeculectomy combined with phacoemulsification and trabeculectomy followed by phacoemulsification: a retrospective cohort study. BMC Ophthalmol. 2021 Apr 24;21(1):188. https://doi.org/10.1186/s12886-021-01949-9

Dong Z, Gong J, Liao R, Xu S. Effectiveness of multiple therapeutic strategies in neovascular glaucoma patients. Med (United States). 2018;97(14). https://doi.org/10.1097/MD.0000000000009897

Dumbrăveanu L, Cușnir V, Bobescu D. A review of neovascular glaucoma. Etiopathogenesis and treatment. Rom J Ophthalmol. 2021 Oct-Dec; 65(4):315-329. https://doi.org/10.22336/rjo.2021.66

Havens SJ, Gulati V. Neovascular glaucoma. Dev Ophthalmol. 2015;55:196-204. https://doi.org/10.1159/000431196

Kawabata K, Shobayashi K, Iwao K, Takahashi E, Tanihara H, Inoue T. Efficacy and safety of Ex-PRESS® mini shunt surgery versus trabeculectomy for neovascular glaucoma: a retrospective comparative study. BMC Ophthalmology 2019;19(1):75. https://doi.org/10.1186/s12886-019-1083-4

Kim M, Lee C, Payne R, Yue BY, Chang JH, Ying H. Angiogenesis in Glaucoma Filtration Surgery and Neovascular Glaucoma. A review. Surv Ophthalmol. 2015 Nov-Dec;60(6):524-35. https://doi.org/10.1016/j.survophthal.2015.04.003

Mariotti C, Dahan E, Nicolai M, Levitz L, Bouee S. Long-term outcomes and risk factors for failure with the EX-press glaucoma drainage device. Eye (Lond). 2014 Jan; 28(1):1-8. https://doi.org/10.1038/eye.2013.234

Moisseiev E, Zunz E, Tzur R, Kurtz S, Shemesh G. Standard Trabeculectomy and Ex-PRESS Miniature Glaucoma Shunt: A Comparative Study and Literature Review. J Glaucoma. 2015 Aug; 24(6):410-6. https://doi.org/10.1097/IJG.0000000000000047

Rodrigues GB, Abe RY, Zangalli C, Sodre SL, Donini FA, Costa DC, et al. Neovascular glaucoma. A Review. 2016; 2(1):1-10. https://doi.org/10.1186/s40942-016-0051-x

Schuster AK, Erb C, Hoffmann EM, Dietlein T, Pfeiffer N. The diagnosis and treatment of glaucoma. Dtsch Arztebl Int. 2020;117(13):225-34. https://doi.org/10.3238/arztebl.2020.0225

Shekhawat N, Neola R, Goyal K, Khilnani K, Saini R. Role of intravitreal Anti-VEGF as an adjunct in neovascular glaucoma management. Contributors. 2019;18(11):51-6.

Sun Y, Liang Y, Zhou P, Wu H, Hou X, Ren Z, et al. Anti-VEGF treatment is the key strategy for neovascular glaucoma management in the short term. BMC Ophthalmol. 2016;16(1):1-8. https://doi.org/10.1186/s12886-016-0327-9

Yang H, Yu X, Sun X. Neovascular glaucoma: Handling in the future. Taiwan J Ophthalmology. 2018; 8:53-5. https://doi.org/10.4103/tjo.tjo_39_18